The safety, tolerability and biochemical efficacy of extended release niacin and laropiprant in a major randomised clinical trial by Haynes, R

Optical microscopy of materials / by Haynes, R. (Raymond), 1927-

PCSK9 inhibition: ready for prime time in CKD? by Mafham, M, Haynes, R

Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: UK Heart and Renal Protection (UK HARP)-III. Rationale, trial... by Haynes, R, Judge, P

Homocysteine, the kidney, and vascular disease. by Haynes, R, Clarke, R

Commentary: Controversies in NICE guidance on chronic kidney disease by Landray, M, Haynes, R

Proteinuria. by Haynes, J, Haynes, R

TaleNeprilysin and Neprilysin inhibition in chronic kidney disease by Judge, PK, Haynes, R

The Health and Care Act 2022: challenges and priorities for embedding research in the NHS by Toh, CH, Haynes, R

Screening for risk with albuminuria: should we start from here? by Haynes, R, Winearls, C

Commentary: Controversies in NICE guidance on chronic kidney disease. by Landray, M, Haynes, R

Chronic kidney disease: Does serum phosphate predict death and ESRD in CKD patients? by Haynes, R, Wheeler, D

Pooled RCTs: Atorvastatin did not increase renal-related serious adverse events by Herrington, W, Haynes, R

Reply from the editors. by Glasziou, P, Haynes, R

Fluvastatin for reduction of cardiovascular risk in patients with moderate to severe renal insufficiency. by Haynes, R, Armitage, J

Alemtuzumab: right drug, right dose? by Haynes, R, Friend, P

Chronic kidney disease: Does serum phosphate predict death and ESRD in CKD patients? by Haynes, R, Wheeler, D

Homocysteine, the kidney, and vascular disease Moderate differences in homocysteine concentrations do not cause vascular disease by Haynes, R, Clarke, R

Niacin: old habits die hard. by Haynes, R, Rahimi, K

Kidney disease trials for the 21st century: innovations in design and conduct by Herrington, W, Staplin, N, Haynes, R